Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …

Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer …

Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 …

Introduction Approximately half of the 13.4 billion COVID-19 vaccine doses administered
globally were inactivated or viral vector platforms. The harmonization and optimization of …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX …

Abstract PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant
spike protein COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well …

Background NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-
CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …

Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle
vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease …

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has become a global threat. Although non-pharmaceutical …

1. Dolgin E. How protein-based COVID vaccines could change the pandemic. Nature 2021;
599: 359-60. 2. An Advisory Committee Statement (ACS) National Advisory Committee on …